 "Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma")
: The US Food and Drug Administration has put on hold the phase 2/3 clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin, in USA.
According to a press release by Ocugen Inc , Bharat Biotech's partner for US and Canada for Covaxin, the FDA's decision was based on the US firm's decision to voluntarily implement a temporary pause in dosing participants of the jab, following the World Health Organisation's observations on Covaxin manufacturing plants in India.
This is a result of the company's decision to voluntarily implement a temporary pause in dosing participants of OCU-002 while it evaluates statements made by the World Health Organization following their inspection of Bharat Biotech International Limited's (BBIL) manufacturing facility, Ocugen said on April 12.
WHO had earlier suspended the supply of Covaxin through US procurement agencies, after its inspectors identified GMP (good manufacturing practice) deficiencies in the Bharat Biotech's manufacturing plants.
Sources had said the city-based firm however, said it had not supplied the Covid vaccine to any UN agency and no impact of the suspension would be felt.
OCU-002 is Ocugen's Phase 3 immuno-bridging study of Covaxin.
The company said it will work with the FDA to address any questions. The FDA, in February, lifted its clinical hold on Ocugen's Investigational New Drug application (IND) to evaluate the Covaxin.
After WHO inspection, Bharat Biotech had said it is temporarily slowing down production of Covaxin across its manufacturing units for facility optimisation as it has already completed its supply obligations to procurement agencies and foresees decrease in demand.
The company further said after the recent WHO post Emergency Use Listing (EUL) inspection, it is working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
